APSARD and Tris Pharma Announce the Inaugural Tris Research Award in ADHD

Friday, January 17, 2020 Mental Health News
Email Print This Page Comment bookmark
Font : A-A+

MONMOUTH JUNCTION, N.J., Jan. 17, 2020 /PRNewswire/ -- The American Professional Society of ADHD and Related Disorders (APSARD) is a U.S.-based international organization of health professionals and scientists focusing exclusively on ADHD and related disorders and Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, today jointly announced its multi-year, inaugural research award to advance and recognize outstanding research in the field of ADHD. 

The award recognizes innovative research that facilitates a better understanding of the diagnosis, recognition and/or treatment of ADHD and related disorders. APSARD is solely responsible for the management, decision making and oversight of this award. The recipient of the award will be independently selected by the APSARD Program Committee.

APSARD is grateful to Tris for its commitment to a multi-year support of this award. 

Tris' Founder and CEO, Ketan Mehta commented, "We are honored to have this opportunity to partner with APSARD to recognize outstanding research in the field of ADHD and advance APSARD's goal of supporting cutting edge research."   

The posters at the 2020 APSARD Annual Meeting present the results of original research on epidemiology, etiology, pathophysiology, pharmacologic agents, diagnostic and therapeutic issues, and innovative services or outcomes of services provided to the ADHD and related disorders patient population.  The 2020 award will be chosen from a field of 74 scientific posters presented at the 2020 APSARD Annual Meeting which will be held in Washington DC, from January 16-19.

About Tris Pharma

Tris Pharma is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines that address unmet patient needs.  Tris has pioneered the delivery of long-acting liquid, chewable, orally-disintegrating, and film strip dosage forms that can accommodate the unique needs of a wide variety of patients.  Tris' fully integrated research, manufacturing, medical and commercial facilities are located in Central New Jersey.  For more information, please visit www.trispharma.com

About APSARD

The American Professional Society of ADHD and Related Disorders is a U.S.-based international organization of health professionals and scientists focusing exclusively on ADHD and related disorders. The Organization works to improve the quality of care for ADHD patients through shared research, best practices, evidence-based education and training. 

Cision View original content:http://www.prnewswire.com/news-releases/apsard-and-tris-pharma-announce-the-inaugural-tris-research-award-in-adhd-300989003.html

SOURCE Tris Pharma, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Diabetes Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store